Sigyn Therapeutics (SIGY) Accounts Payables (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Accounts Payables of $773604.0 for Q3 2025, up 6.0% sequentially from $729846.0 in Q2 2025, and up 26.48% YoY from $611643.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Accounts Payables (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Accounts Payables for 10 years, with the latest figure at $773604.0 in Q3 2025.
- Quarterly Accounts Payables rose 26.48% year-over-year to $773604.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $773604.0 (up 26.48% YoY) and the FY2024 annual result came in at $608384.0, up 31.79% from the prior year.
- Accounts Payables advanced to $773604.0 in Q3 2025 per SIGY's latest filing, from $729846.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $773604.0 in Q3 2025 and troughed at $32874.0 in Q3 2021.
- A 5-year average of $375152.1 and a median of $339944.0 in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2021 and 2022: Accounts Payables retreated 15.15% in 2021, then jumped 830.83% in 2022.
- Over 5 years, Accounts Payables stood at $39674.0 in 2021, then soared by 725.52% to $327517.0 in 2022, then soared by 40.95% to $461646.0 in 2023, then soared by 31.79% to $608384.0 in 2024, then rose by 27.16% to $773604.0 in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $773604.0, $729846.0, and $672040.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 773,604.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 773,604.00 |
| Jun 30, 2025 | 729,846.00 |
| Mar 31, 2025 | 672,040.00 |
| Dec 31, 2024 | 608,384.00 |
| Sep 30, 2024 | 611,643.00 |
| Jun 30, 2024 | 488,364.00 |
| Mar 31, 2024 | 529,450.00 |
| Dec 31, 2023 | 461,646.00 |
| Sep 30, 2023 | 361,629.00 |
| Jun 30, 2023 | 339,944.00 |
| Mar 31, 2023 | 265,085.00 |
| Dec 31, 2022 | 327,517.00 |
| Sep 30, 2022 | 306,000.00 |
| Jun 30, 2022 | 299,317.00 |
| Mar 31, 2022 | 196,147.00 |
| Dec 31, 2021 | 39,674.00 |
| Sep 30, 2021 | 32,874.00 |
| Jun 30, 2021 | 40,666.00 |
| Mar 31, 2021 | 44,060.00 |
| Dec 31, 2020 | 16,005.00 |